Clinical Trial Update: Safety and Clinical Activity of Nivatrotamab in Relapsed/Recurrent Metastatic Small-cell Lung Cancer [Phase 1, Phase 2]

View source ↗

Summary

A clinical trial updating safety and activity of Nivatrotamab in relapsed/recurrent metastatic small-cell lung cancer has been terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• Nivatrotamab

Snippet

Sponsor: Y-mAbs Therapeutics | Conditions: SCLC | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2023-08-14